Alnylam Pharmaceuticals (ALNY) Stock Price

$234.6 1.8%

Sign up
to add to portfolio

AI Score

Hold
  • Alternative

    7
  • Fundamental

    7
  • Technical

    4

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Alnylam Pharmaceuticals, AI stock picks, stock alerts and much more.

Sign up

ALNY AI Stock Analysis

Financial Performance

The financial performance of Alnylam Pharmaceuticals has shown some negative trends in the last quarter. Revenue was reported at $500.9M, showing a decrease by -24.1% from the previous quarter. Gross profit also decreased by -29.8%, standing at $415M, and operating income showed a significant drop of -258.2%, with a loss of -$76.9M. The EBITDA ratio was negative at -0.12, indicating that operating expenses are higher than its earnings.

Stock Price

The stock price is currently trading at $255.28, which shows an increase of 4% in the last month and an impressive growth of 32% year over year compared to the stock's 200-day moving average of $226.56. However, it's important to note that the PE ratio is quite high at -97.44 and the EPS stands at -2.62, suggesting potential overvaluation.

Alternative Data Signals

In terms of alternative data signals, web traffic for Alnylam Pharmaceuticals has slightly decreased by -5.3% month over month but still maintains a decent volume with approximately 55958 visitors per month which indicates sustained interest in the company's activities or products/services among internet users.

The number of job openings has decreased both monthly (-4.3%) and yearly (-22%), possibly indicating restructuring or cost-saving measures within the company.

About two-thirds (66%) employees report having a positive business outlook which is up by +3% from last month but down yearly by -12%. This could suggest mixed sentiments about future prospects within the organization.

Social media followership on Twitter (+1%), Instagram (+38.6%), and Facebook (+124.8%) have all increased over the last 90 days, indicating growing public interest or engagement with the company.

Conclusion

The analysis of Alnylam Pharmaceuticals' stock performance is neutral to slightly bullish due to positive year-over-year stock price growth and social media engagement but tempered by recent declines in financial performance indicators and employee business outlook.

Note: This AI Stock Analysis is based on data as of January 13. Our members can refresh and get access to an up-to-date AI stock analysis.

Sign up

Alnylam Pharmaceuticals (ALNY) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Alnylam Pharmaceuticals (ALNY), currently trading at $234.6, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About ALNY

LSE
  • Alnylam Pharmaceuticals, Inc.

  • Symbol

    ALNY

  • Market

    NASDAQ

  • Industry

    Biotechnology

  • Market Cap

    30.5B

Similar Stocks

CPRX Catalyst Pharmaceuticals
CPRX
$22.52
1.5%
5
INO Inovio Pharmaceuticals
INO
$1.74
1.2%
1
MRNA Moderna
MRNA
$24.72
1.9%
3
AVXL Anavex Life Sciences
AVXL
$8.95
1.2%
5
BBIO BridgeBio Pharma
BBIO
$33.87
0.1%
4

ALNY Alternative Data

Web Traffic

Alnylam Pharmaceuticals receives an estimated 67912 monthly visitors to alnylam.com.

  • Web Traffic

    67912

  • Change from Previous Month

    1.1%

  • 3 Month Change

    6.4%

  • YoY Change

    6.4%

News Mentions

Alnylam Pharmaceuticals was mentioned 0 times in the news yesterday.

  • News Mentions

    0

  • Daily Change

    100%

  • 1 Month Change

    100%

  • 3 Month Change

    100%

Reddit Mentions

Alnylam Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

Twitter Followers

Alnylam Pharmaceuticals has 17,092 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.2% over the last month.

  • Twitter Followers

    17092

  • Daily Change

    0%

  • 1 Month Change

    0.2%

  • 3 Month Change

    0%

  • YoY Change

    0%

Facebook Engagement

Alnylam Pharmaceuticals has engaged 247 users via their Facebook Page over the last 7 days.

  • Facebook Engagement

    247

  • Daily Change

    11.8%

  • 1 Month Change

    2145.5%

  • 3 Month Change

    2145.5%

  • YoY Change

    2145.5%

Instagram Followers

Alnylam Pharmaceuticals has 1,934 Instagram Followers on its main Instagram account, up by 4.4% over the last month.

  • Instagram Followers

    1934

  • Daily Change

    0.2%

  • 1 Month Change

    4.4%

  • 3 Month Change

    8.1%

  • YoY Change

    8.1%

Youtube Subscribers

Alnylam Pharmaceuticals has 2,630 subscribers on its main Youtube channel, up by 0.8% over the last month.

  • Youtube Subscribers

    2630

  • Daily Change

    0.4%

  • 1 Month Change

    0.8%

  • 3 Month Change

    3.1%

  • YoY Change

    3.1%

LinkedIn Followers

231,066 are following Alnylam Pharmaceuticals on LinkedIn, up by 2.8% over the last month.

  • LinkedIn Followers

    231066

  • Daily Change

    0.1%

  • 1 Month Change

    2.8%

  • 3 Month Change

    6.3%

Job Postings

Alnylam Pharmaceuticals has an estimated 90 open job postings, which is down -1.1% over the last month.

  • Job Postings

    90

  • Daily Change

    1.1%

  • 1 Month Change

    1.1%

  • 3 Month Change

    30.8%

  • YoY Change

    30.8%

LinkedIn Employees

According to LinkedIn, Alnylam Pharmaceuticals has 2,491 employees, up by 0% over the last month.

  • LinkedIn Employees

    2491

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    2.8%

  • YoY Change

    2.8%

Business Outlook

According to employee reviews, the business outlook among employees at Alnylam Pharmaceuticals is 66 out of 100 (bullish).

  • Business Outlook

    66

  • Change from Previous Month

    3.1%

  • 3 Month Change

    0%

  • YoY Change

    0%

ALNY Financials

ALNY Key Metrics
  • Total Revenue

    $593.2M

  • Net Income

    -$83.8M

  • Earnings per Share

    -$0.65

  • Free cash flow

    -$103.8M

  • EBITDA

    -$155M

  • EBITDA Ratio

    -0.261288

  • Total Assets

    $4.2B

ALNY 2-year Revenue & Income
ALNY 2-year Free Cash Flow

ALNY Technicals

ALNY SMA
ALNY RSI

FAQ

What's the current price of Alnylam Pharmaceuticals (ALNY) Stock?
The price of an Alnylam Pharmaceuticals (ALNY) share is $234.6.

What's the market cap of Alnylam Pharmaceuticals?
The current market cap of Alnylam Pharmaceuticals is 30.5B.

Should I buy or sell ALNY?
Alnylam Pharmaceuticals shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Alnylam Pharmaceuticals is better viewed as a hold or accumulate position while waiting for further developments.

Is Alnylam Pharmaceuticals a good investment?
The current analysis of Alnylam Pharmaceuticals' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Alnylam Pharmaceuticals' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.

Is now a good time to buy Alnylam Pharmaceuticals (ALNY) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Alnylam Pharmaceuticals stock is currently neutral, suggesting a cautious approach might be wise.

What are some stocks similar to Alnylam Pharmaceuticals (ALNY) that investors often compare it to?
Alnylam Pharmaceuticals (ALNY) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.

What is the forecast for Alnylam Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Alnylam Pharmaceuticals' stock price to be around $247.5 in 2026. Starting from the current price of $234.6, this represents a 5.5% change in price, indicating a bullish outlook for the stock.

How to buy Alnylam Pharmaceuticals (ALNY) Stock?
Alnylam Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Alnylam Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.